Emily M. Leproust - 04 Nov 2024 Form 4 Insider Report for Twist Bioscience Corp (TWST)

Role: Chief Executive Officer, Director
Signature: /s/ Dennis Cho, as Attorney-in-Fact for Emily M. Leproust
Issuer symbol: TWST
Transactions as of: 04 Nov 2024
Net transactions value: -$201,211
Form type: 4
Filing time: 06 Nov 2024, 17:06:22 UTC
Previous filing: 04 Oct 2024
Next filing: 15 Nov 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TWST	Common Stock	Award	$0	+80,855	+17%	$0.000000	562,773	04 Nov 2024	Direct	F1
transaction	TWST	Common Stock	Award	$0	+45,954	+8.2%	$0.000000	608,727	04 Nov 2024	Direct	F1
transaction	TWST	Common Stock	Sale	$201,211	-4,841	-0.8%	$41.56	603,886	04 Nov 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TWST	Employee Stock Option (right to buy)						0	04 Nov 2024	Common Stock	0	$5.95	Direct	F3
holding	TWST	Employee Stock Option (right to buy)						150,879	04 Nov 2024	Common Stock	0	$8.82	Direct	F4
holding	TWST	Employee Stock Option (right to buy)						266,539	04 Nov 2024	Common Stock	0	$26.66	Direct	F5
holding	TWST	Employee Stock Option (right to buy)						131,290	04 Nov 2024	Common Stock	0	$23.33	Direct	F6
holding	TWST	Employee Stock Option (right to buy)						64,950	04 Nov 2024	Common Stock	64,950	$67.85	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents performance stock units for which target criteria was determined to have been met on November 4, 2024. 60% of the PSUs remain subject to time-based vesting and will vest on October 1,2025, subject to continued service or acceleration of vesting as provided in the award agreement.
F2	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3	The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F4	The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F5	20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F6	25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F7	Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.